Drugmaker asks Supreme Court to halt ruling blocking online access to mifepristone

Danco Laboratories has requested the U.S. Supreme Court to block a recent appellate court decision that restricts mail-order access to the abortion pill mifepristone. This decision by the 5th U.S. Circuit Court of Appeals mandates that the drug be distributed only in person at clinics, challenging the FDA’s regulations and creating confusion in medical decisions. The ruling is seen as a victory for abortion opponents who argue that mail-order prescriptions undermine state bans, particularly in Louisiana, where the law recognizes unborn children as legal persons from conception. The FDA, under President Trump, has been reviewing the safety of mifepristone, but the process remains incomplete. Since the overturning of Roe v. Wade in 2022, mail-order prescriptions have become crucial for accessing abortions, especially in states with bans. Critics argue that restricting telemedicine options will severely limit access for many, including those in rural areas or facing personal challenges. QUESTION: How might the restriction of mail-order access to abortion pills impact individuals living in states with strict abortion laws?